April 12th 2024
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Guiding Through Challenges: Insights for Caregivers of R/R MM Patients
February 1st 2024Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Patient-Centric Care in R/R MM
February 1st 2024Nurse Linne-Mclaren provides her insights into the proactive measures, monitoring strategies, and experiences related to talquetamab-associated adverse events, along with a broader perspective on prophylactic measures for managing potential adverse events in bispecific therapies.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.
Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific
January 25th 2024Oncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.
Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.
Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma
Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.
Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCT
January 19th 2024Experts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.